MDS 2023 | The role of RNA modifications in MDS and AML
Jason Cheng, The University of Chicago, Chicago, IL, comments on the role of RNA modifications in the context of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Dr Cheng explains that little is currently known about the impact of RNA modifications on chromatin structures and gene expression in the context of these diseases. Dr Cheng therefore emphasizes that this field should be further studied and applied to prognostication and treatment for these patient groups. This interview took place at the 17th International Congress on Myelodysplastic Syndromes (MDS) 2023, held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
